Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment

Blood

Volumn 100, Issue 8, 2002, Pages 2957-2964

  Daskalakis, Michael ^{a,b,c,d,e,f,g}   Nguyen, Tudung T ^{a,b,c,d,e,f,g}   Nguyen, Carvell ^{a,b,c,d,e,f,g}   Guldberg, Per ^{a,b,c,d,e,f,g}   Köhler, Gabriele ^{a,b,c,d,e,f,g}   Wijermans, Pierre ^{a,b,c,d,e,f,g}   Jones, Peter A ^{a,b,c,d,e,f,g}   Lübbert, Michael ^{a,b,c,d,e,f,g}  

^a UNIVERSITY OF FREIBURG   (Germany)

^b LEYENBURG HOSPITAL   (Netherlands)

^c Institute of Cancer Biology   (Denmark)

^d DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^e UNIVERSITY OF FREIBURG   (Germany)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; CYCLIN DEPENDENT KINASE; GENE PRODUCT; PROTEIN P15; PROTEIN P16;

ADULT; AGED; ALLELE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLAST CELL CRISIS; BLOOD DISEASE; BONE MARROW BIOPSY; BONE MARROW CELL; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPENIA; DEMETHYLATION; DENATURING GRADIENT GEL ELECTROPHORESIS; DNA SEQUENCE; DOSE RESPONSE; ENZYME INHIBITION; FEMALE; GENOTYPE; HIGH RISK POPULATION; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METHYLATION; MONONUCLEAR CELL; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SEQUENCE ANALYSIS; TREATMENT OUTCOME;

EID: 0037108309     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V100.8.2957     Document Type: Article

References (51)

1. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genetics. 1999;21:163-167.
2. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature. 1983;301:89-92.
3. Wahlfors J, Hiltunen H, Heinonen K, Hamalainen E, Alhonen L, Jänne J. Genomic hypomethylation in human chronic lymphocytic leukemia. Blood. 1992;80:2074-2080.
4. Nakayama M, Wada M, Harada T, et al. Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. Blood. 1998; 92:4296-4307.
5. Herman JG, Civin CI, Issa JP, Collector MI, Sharkis SJ, Baylin SB. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res. 1997;57:837-841.
6. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 1998;72:141-196.
7. Drexler HG. Review of alterations of cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia. 1998;12:845-859.
8. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell. 1980; 20:85-93.
9. Wilson VL, Jones PA, Momparler RL. Inhibition of DNA methylation in L1210 leukemic cells by 5-Aza-2′-deoxycytidine as a possible mechanism of chemotherapeutic action. Cancer Res. 1983; 43:3493-3496.
10. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429-2440.
11. Wijermans PW, Krulder JW, Huijgens PC, Neve P. Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia. 1997;11:1-5.
12. Wijermans PW, Lübbert M, Verhoef G, et al. Lowdose 5-Aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome; a multicenter phase II study in elderly patients. J Clin Oncol. 2000;18:956-962.
13. Lübbert M, Wijermans PW, Kunzmann R, et al. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-AZA-2′-deoxycytidine. Brit J Haematol. 2001;114:349-357.
14. Pinto A, Attadia V, Fusco A, Ferrara F, Spada OA, Di Fiore PP. 5-Aza-2′-deoxcytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood. 1984;64: 922-929.
15. Jüttermann R, Li E, Jaenisch R. Toxicity of 5-Aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyl-transferase rather than DNA demethylation. Proc Nat Acad Sci U S A. 1994;91:11797-11801.
16. Li JM, Nichols MA, Chandrasekharan S, Xiong Y, Wang XF. Transforming growth factor beta activates the promoter of cyclin-dependent kinase inhibitor p15INK4B through an Sp1 consensus site. J Biol Chem. 1995;270:26750-26753.
17. Jen J, Harper JW, Bigner SH, et al. Deletion of pl 6 and p15 genes in brain tumors. Cancer Res. 1994;54:6353-6358.
18. Hannon GJ, Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature. 1994;371:257-261.
19. Reynisdottir I, Massague J. The subcellular locations of p15(INK4B) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev. 1997;11:492-503.
20. Uchida T, Kinoshita T, Nagai H, et al. Hypermethylation of the p15/INK4B gene in myelodysplastic syndromes. Blood. 1997;4:1403-1409.
21. Quesnel B, Guillerm G, Vereecque R, et al. Methylation of the p15/INK4B gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood. 1998;8:2985-2990.
22. Malumbres M, Perez de Castro I, Santos J, et al. Inactivation of the cyclin-dependent kinase inhibitor p15INK4b by deletion and de novo methylation with independence of p16INK4a alterations in murine primary T-cell lymphomas. Oncogene. 1997;14:1361-1370.
23. Herman JG, Jen J, Merlo A, Baylin SB. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res. 1996;56:722-727.
24. Gonzalgo ML, Jones PA. Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE). Nucl Acids Res. 1997; 12:2529-2531.
25. Gonzalgo ML, Bender CM, You EH, et al. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. Cancer Res. 1997;57:5336-5347.
26. Frommer M, McDonald LE, Millar DS, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A. 1992;89:1827-1831.
27. Nguyen TT, Mohrbacher AF, Tsai YC, et al. Quantitative measure of p15 and c-abl methylation in chronic myelogenous leukemia. Blood. 2000;95: 2990-2992.
28. Aggerholm A, Guldberg P, Hokland M, Hokland P. Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia. Cancer Res. 1999;59:436-441.
29. Nguyen C, Liang G, Nguyen TT, et al. Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells. J Nat Cancer Inst. 2001;93:1465-1472.
30. Teofili L, Rutella S, Chiusolo P, et al. Expression of p15INK4B in normal hematopoiesis. Exp Hematol. 1998;26:1133-1139.
31. Falini B, Abdulaziz Z, Gerdes J, et al. Description of a sequential staining procedure for double immunoenzymatic staining of pairs of antigens using monoclonal antibodies. J Immunol Methods. 1986;93:265-273.
32. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079.
33. Momparler RL, Bouffard DY, Momparler LF, Dionne J, Belanger K, Ayoub J. Pilot phase I-II study on 5-Aza-2′-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs. 1997;8:358-368.
34. Lin KT, Momparler RL, Rivard GE. Sample preparation for the determination of 5-Aza-2′-deoxycytidine in plasma by high-performance liquid chromatography. J Chromat. 1985;345:162-167.
35. van Groeningen CJ, Leyva A, O'Brien AM, Gall HE, Pinedo HM. Phase I and pharmacokinetic study of 5-Aza-2′-deoxycytidine (NSC 127716) in cancer patients. Cancer Res. 1986;46:4831-4836.
36. Pinto A, Zagonel V. 5-Aza-2′-deoxycytidine (Decitabine) and 5-Azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. Leukemia. 1993;7(suppl 1):51-60.
37. Cote S, Sinnett D, Momparler RL. Demethylation by 5-Aza-2′-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor beta gene in human colon carcinoma cells. Anticancer Drugs. 1998;9:743-750.
38. Bender CM, Pao MM, Jones PA. Inhibition of DNA methylation by 5-Aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res. 1998;58:95-101.
39. Bender CM, Gonzalgo ML, Gonzales FA, et al. Roles of cell division and gene transcription in the methylation of CpG islands. Mol Cell Biol. 1999; 19:6690-6698.
40. Melki JR, Vincent PC, Clark SJ. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res. 1999;59:3730-3740.
41. Dodge JE, List AF, Futscher BW. Selective variegated methylation of the p15 CpG island in acute myeloid leukemia. Int J Cancer. 1998;78:561-567.
42. Chen YX, Li B, Yang J, et al. p15INK4B gene expression and hypermethylation in bone marrow cells of patients with acute myeloid leukemia [abstract]. Blood. 1998;92:602a.
43. Cameron EE, Baylin SB, Herman JG. P15INK4B CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. Blood. 1999;94:2445-2451.
44. Jones PL, Veenstra GJ, Wade PA, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genetics. 1998;19: 187-191.
45. Nan X, Ng HH, Johnson CA, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature. 1998;393:386-389.
46. Humphries RK, Dover G, Young NS, et al. 5-Azacytidine acts directly on both erythroid precursors and progenitors to increase production of fetal hemoglobin. J Clin Invest. 1985;75:547-557.
47. Burns LJ, Glauber JG, Ginder GD. Butyrate induces selective transcriptional activation of a hypomethylated embryonic globin gene in adult erythroid cells. Blood. 1988;72:1536-1542.
48. Nyce J. Drug-induced DNA hypermethylation and drug resistance in human tumors. Cancer Res. 1989;49:5829-5836.
49. Toyota M, Kopecky KJ, Toyota MO, Jair KW, Willman CL, Issa JP. Methylation profiling in acute myeloid leukemia. Blood. 2001;97:2823-2829.
50. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG islands methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999;96:8681-8686.
51. Karpf AR, Peterson PW, Rawlins JT, et al. Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells. Proc Natl Acad Sci U S A. 1999;96:14007-14012.